No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: Implications for gene panel testing

Journal of Medical Genetics

Volumn 53, Issue 5, 2016, Pages 298-309

  Easton, Douglas F ^a   Lesueur, Fabienne ^b   Decker, Brennan ^a,c   Michailidou, Kyriaki ^a,d   Li, Jun ^e   Allen, Jamie ^a   Luccarini, Craig ^a   Pooley, Karen A ^a   Shah, Mitul ^a   Bolla, Manjeet K ^a   Wang, Qin ^a   Dennis, Joe ^a   Ahmad, Jamil ^f   Thompson, Ella R ^g,h   Damiola, Francesca ⁱ   Pertesi, Maroulio ^f   Voegele, Catherine ^f   Mebirouk, Noura ^b   Robinot, Nivonirina ^f   Durand, Geoffroy ^f   Forey, Nathalie ^f   Luben, Robert N ^a   Ahmed, Shahana ^a   Aittomäki, Kristiina ^j   Anton Culver, Hoda ^k   Arndt, Volker ^l   Baynes, Caroline ^a   Beckman, Matthias W ^h,m   Benitez, Javier ^n,o   Van Den Berg, David ^p   Blot, William J ^q,r   Bogdanova, Natalia V ^s   Bojesen, Stig E ^t,u   Brenner, Hermann ^l   Chang Claude, Jenny ^l,v   Chia, Kee Seng ^w   Choi, Ji Yeob ^x   Conroy, Don M ^a   Cox, Angela ^y   Cross, Simon S ^y   Czene, Kamila ^z   Darabi, Hatef ^z   Devilee, Peter ^aa   Eriksson, Mikael ^z   Fasching, Peter A ^m,ab   Figueroa, Jonine ^ac,ad   Flyger, Henrik ^t   Fostira, Florentia ^ae   García Closas, Montserrat ^ac   Giles, Graham G ^af,ag   Glendon, Gord ^ah   González Neira, Anna ⁿ   Guénel, Pascal ^ai,aj   Haiman, Christopher A ^p   Hall, Per ^z   Hart, Steven N ^ak   Hartman, Mikael ^w   Hooning, Maartje J ^al   Hsiung, Chia Ni ^am   Ito, Hidemi ^an   Jakubowska, Anna ^ao   James, Paul A ^g,h   John, Esther M ^ap,aq,ar   Johnson, Nichola ^as   Jones, Michael ^as   Kabisch, Maria ^l   Kang, Daehee ^x   Kosma, Veli Matti ^g,at,au   Kristensen, Vessela ^av,aw,ax   Lambrechts, Diether ^ay,az   Li, Na ^g,ba   Myöhänen, Eija ^cg   Kemiläinen, Helena ^cg   Lindblom, Annika ^z   Long, Jirong ^r   Lophatananon, Artitaya ^bb   Lubinski, Jan ^ao   Mannermaa, Arto ^at,au   Manoukian, Siranoush ^bc   Margolin, Sara ^z   Matsuo, Keitaro ^an   Meindl, Alfons ^bd   Mitchell, Gillian ^g,h   Muir, Kenneth ^bb,be   Nevelsteen, Ines ^bf,bg   Van Den Ouweland, Ans ^al   Peterlongo, Paolo ^bh   Phuah, Sze Yee ^bi,bj   Pylkäs, Katri ^bk,bl   Rowley, Simone M ^g   Sangrajrang, Suleeporn ^bm   Schmutzler, Rita K ^bn,bo   Shen, Chen Yang ^am,bp   Shu, Xiao Ou ^r   Southey, Melissa C ^h   Surowy, Harald ^l,bq   Swerdlow, Anthony ^as   Teo, Soo H ^bi,bj   Tollenaar, Rob A E M ^aa   Tomlinson, Ian ^br   Torres, Diana ^l,bs   Truong, Thérèse ^ai,aj   Vachon, Celine ^ak   Verhoef, Senno ^bt   Wong Brown, Michelle ^bu   Zheng, Wei ^r   Zheng, Ying ^bv   Nevanlinna, Heli ^j   Scott, Rodney J ^bu,bw   Andrulis, Irene L ^ah,bx   Wu, Anna H ^p   Hopper, John L ^h   Couch, Fergus J ^ak   Winqvist, Robert ^bk,bl   Burwinkel, Barbara ^l,bq   Sawyer, Elinor J ^by   Schmidt, Marjanka K ^bt   Rudolph, Anja ^l   Dörk, Thilo ^s   Brauch, Hiltrud ^l,bz,ca   Hamann, Ute ^l   Neuhausen, Susan L ^cb   Milne, Roger L ^af,ag   Fletcher, Olivia ^as   Pharoah, Paul D P ^a   Campbell, Ian G ^g,h   Dunning, Alison M ^a   Le Calvez Kelm, Florence ^f   Goldgar, David E ^cc,cd   Tavtigian, Sean V ^cd   Chenevix Trench, Georgia ^e   Kleivi, Kristine ^ax,ce   Ottestad, Lars ^bf   Kåresen, Rolf ^av   Langerød, Anita ^bf   Schlichting, Ellen ^cf   Holmen, Marit Muri ^av   Sauer, Toril ^cg   Haakensen, Vilde ^bf   Engebråten, Olav ^av,aw   Naume, Bjørn ^bf   Kiserud, Cecile E ^av   Reinertsen, Kristin V ^av   Helland, Åslaug ^av,bf   Riis, Margit ^cf   Bukholm, Ida ^av,cg   Lønning, Per Eystein ^ch,ci   Nord, Silje ^bf   Alnæs, Grethe I Grenaker ^bf   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSERM U900   (France)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ CENTRE LÉON BÉRARD   (France)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^m UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁿ Centro Nacional de Investigaciones Oncológicas   (Spain)

^o CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^p UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^q INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^r VANDERBILT INGRAM CANCER CENTER   (United States)

^s HANNOVER MEDICAL SCHOOL   (Germany)

^t GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^u UNIVERSITY OF COPENHAGEN   (Denmark)

^v UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^w NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^x Seoul National University College of Medicine   (South Korea)

^y UNIVERSITY OF SHEFFIELD   (United Kingdom)

^z KAROLINSKA INSTITUTE   (Sweden)

^aa LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^ab UNIVERSITY OF CALIFORNIA   (United States)

^ac NATIONAL CANCER INSTITUTE   (United States)

^ad UNIVERSITY OF EDINBURGH   (United Kingdom)

^ae INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^af CANCER EPIDEMIOLOGY CENTRE   (Australia)

^ag UNIVERSITY OF MELBOURNE   (Australia)

^ah MOUNT SINAI HOSPITAL   (Canada)

^ai UNIVERSITÉ PARIS SACLAY   (France)

^aj CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^ak MAYO CLINIC   (United States)

^al ERASMUS MEDICAL CENTER   (Netherlands)

^am INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^an AICHI CANCER CENTER HOSPITAL   (Japan)

^ao POMERANIAN MEDICAL UNIVERSITY   (Poland)

^ap CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^aq STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ar STANFORD CANCER INSTITUTE   (United States)

^as INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^at UNIVERSITY OF EASTERN FINLAND   (Finland)

^au KUOPIO UNIVERSITY HOSPITAL   (Finland)

^av OSLO UNIVERSITY HOSPITAL   (Norway)

^aw UNIVERSITY OF OSLO   (Norway)

^ax UNIVERSITY OF OSLO   (Norway)

^ay DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^az UNIVERSITY OF LEUVEN   (Belgium)

^ba HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^bb UNIVERSITY OF WARWICK   (United Kingdom)

^bc NATIONAL CANCER INSTITUTE   (Italy)

^bd TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^be UNIVERSITY OF MANCHESTER   (United Kingdom)

^bf OSLO UNIVERSITY HOSPITAL   (Norway)

^bg UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^bh FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^bi UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^bj CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^bk Laboratory of Cancer Genetics and Tumor Biology   (Finland)

^bl UNIVERSITY OF OULU   (Finland)

^bm NATIONAL CANCER INSTITUTE   (Thailand)

^bn UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^bo UNIVERSITY OF COLOGNE   (Germany)

^bp CHINA MEDICAL UNIVERSITY   (Taiwan)

^bq UNIVERSITY OF HEIDELBERG   (Germany)

^br UNIVERSITY OF OXFORD   (United Kingdom)

^bs PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^bt ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^bu JOHN HUNTER HOSPITAL   (Australia)

^bv Shanghai Municipal Center for Disease Control and Prevention   (China)

^bw JOHN HUNTER HOSPITAL   (Australia)

^bx UNIVERSITY OF TORONTO   (Canada)

^by GUY S HOSPITAL   (United Kingdom)

^bz DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^ca UNIVERSITY OF TÜBINGEN   (Germany)

^cb CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^cc UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^cd UNIVERSITY OF UTAH   (United States)

^ce University of Utah School of Medicine ^*  (Norway)

^cf ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^cg AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^ch UNIVERSITY OF BERGEN   (Norway)

^ci HAUKELAND UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 INTERACTING PROTEIN C TERMINAL HELICASE 1; DEOXYRIBONUCLEOPROTEIN; ESTROGEN RECEPTOR; UNCLASSIFIED DRUG; BRIP1 PROTEIN, HUMAN; DNA BINDING PROTEIN; RNA HELICASE;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DNA SEQUENCE; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EUROPEAN; FEMALE; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NONSENSE MEDIATED MRNA DECAY; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; UNITED KINGDOM; AGED; BREAST NEOPLASMS; CAUCASIAN; COHORT ANALYSIS; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; RISK;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; DNA-BINDING PROTEINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; RISK; RNA HELICASES;

EID: 84959299225     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2015-103529     Document Type: Article

References (43)

1. Ghoussaini M, Pharoah PD, Easton DF. Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning? AmJPathol 2013;183:1038-51
2. Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans DG, Chenevix-Trench G, Rahman N, Robson M, Domchek SM, Foulkes WD. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 2015;372:2243-57
3. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 2001;105:149-60
4. Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S, Andreassen PR, Cantor SB. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer cell 2005;8:255-65
5. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E, Steltenpool J, Rooimans MA, Pals G, Arwert F, Mathew CG, Zdzienicka MZ, Hiom K, De Winter JP, Joenje H. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005;37:934-5
6. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Breast Cancer Susceptibility C, Easton DF, Stratton MR, Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38:1239-41
7. Frank B, Hemminki K, Meindl A, Wappenschmidt B, Sutter C, Kiechle M, Bugert P, Schmutzler RK, Bartram CR, Burwinkel B. BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study. BMC Cancer 2007;7:83
8. Catucci I, Milgrom R, Kushnir A, Laitman Y, Paluch-Shimon S, Volorio S, Ficarazzi F, Bernard L, Radice P, Friedman E, Peterlongo P. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Fam Cancer 2012;11:483-91
9. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, Bowden NA, Scott RJ. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat 2011;127:853-9
10. Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res 2011;13:R20
11. Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 2009;115:51-5
12. Guénard F, Labrie Y, Ouellette G, Joly Beauparlant C, Simard J, Durocher F, BRCAs I. Mutational analysis of the breast cancer susceptibility gene BRIP1/BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. J Hum Genet 2008;53:579-91
13. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A, Turnbull C, Rahman N, Breast, Ovarian Cancer Susceptibility C, Fletcher O, Peto J, Gibson L, Dos Santos Silva I, Nevanlinna H, Muranen TA, Aittomaki K, Blomqvist C, Czene K, Irwanto A, Liu J, Waisfisz Q, Meijers-Heijboer H, Adank M, Hereditary B, Ovarian Cancer Research Group N, van der Luijt RB, Hein R, Dahmen N, Beckman L, Meindl A, Schmutzler RK, Muller-Myhsok B, Lichtner P, Hopper JL, Southey MC, Makalic E, Schmidt DF, Uitterlinden AG, Hofman A, Hunter DJ, Chanock SJ, Vincent D, Bacot F, Tessier DC, Canisius S, Wessels LF, Haiman CA, Shah M, Luben R, Brown J, Luccarini C, Schoof N, Humphreys K, Li J, Nordestgaard BG, Nielsen SF, Flyger H, Couch FJ, Wang X, Vachon C, Stevens KN, Lambrechts D, Moisse M, Paridaens R, Christiaens MR, Rudolph A, Nickels S, Flesch-Janys D, Johnson N, Aitken Z, Aaltonen K, Heikkinen T, Broeks A, Veer LJ, van der Schoot CE, Guenel P, Truong T, Laurent-Puig P, Menegaux F, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Zamora MP, Perez JI, Pita G, Alonso MR, Cox A, Brock IW, Cross SS, Reed MW, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Henderson BE, Schumacher F, Le Marchand L, Andrulis IL, Knight JA, Glendon G, Mulligan AM, kConFab I, Australian Ovarian Cancer Study G, Lindblom A, Margolin S, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Bui QM, Stone J, Dite GS, Apicella C, Tsimiklis H, Giles GG, Severi G, Baglietto L, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Muller H, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Jones M, Figueroa J, Lissowska J, Brinton L, Goldberg MS, Labreche F, Dumont M, Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Bruning T, Network G, Radice P, Peterlongo P, Manoukian S, Bonanni B, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, Jakubowska A, Lubinski J, Jaworska K, Durda K, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Bogdanova NV, Antonenkova NN, Dork T, Kristensen VN, Anton-Culver H, Slager S, Toland AE, Edge S, Fostira F, Kang D, Yoo KY, Noh DY, Matsuo K, Ito H, Iwata H, Sueta A, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Shu XO, Lu W, Gao YT, Cai H, Teo SH, Yip CH, Phuah SY, Cornes BK, Hartman M, Miao H, Lim WY, Sng JH, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Shen CY, Hsiung CN, Wu PE, Ding SL, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Blot WJ, Signorello LB, Cai Q, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Simard J, Garcia-Closas M, Pharoah PD, Chenevix-Trench G, Dunning AM, Benitez J, Easton DF. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013;45:353-61, 361e1-2
14. Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 2008;26:3310-6
15. Kataoka M, Antoniou A, Warren R, Leyland J, Brown J, Audley T, Easton D. Genetic models for the familial aggregation of mammographic breast density. Cancer Epidemiol Biomarkers Prev 2009;18:1277-84
16. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal 2011;17:10-2
17. Li H. Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly. Bioinformatics 2012;28:1838-44
18. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-303
19. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D, Daly MJ. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491-8
20. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014;46:310-15
21. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, O'Malley FP, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D, Breast Cancer Family R. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004;6:R375-89
22. Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vallee MP, Voegele C, Webb PM, Whiteman DC, Australian Cancer S, Breast Cancer Family R, Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast C, Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009;85:427-46
23. Le Calvez-Kelm F, Lesueur F, Damiola F, Vallee M, Voegele C, Babikyan D, Durand G, Forey N, McKay-Chopin S, Robinot N, Nguyen-Dumont T, Thomas A, Byrnes GB, Breast Cancer Family R, Hopper JL, Southey MC, Andrulis IL, John EM, Tavtigian SV. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res 2011;13:R6
24. Park DJ, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, Hammet F, Neuhausen SL, John EM, Andrulis IL, Terry MB, Daly M, Buys S, Le Calvez-Kelm F, Lonie A, Pope BJ, Tsimiklis H, Voegele C, Hilbers FM, Hoogerbrugge N, Barroso A, Osorio A, Breast Cancer Family R, Kathleen Cuningham Foundation Consortium for Research into Familial Breast C, Giles GG, Devilee P, Benitez J, Hopper JL, Tavtigian SV, Goldgar DE, Southey MC. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 2012;90:734-9
25. Le Calvez-Kelm F, Oliver J, Damiola F, Forey N, Robinot N, Durand G, Voegele C, Vallee MP, Byrnes G, Registry BC, Hopper JL, Southey MC, Andrulis IL, John EM, Tavtigian SV, Lesueur F. RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study. PLoS ONE 2012;7:e52374
26. Park DJ, Tao K, Le Calvez-Kelm F, Nguyen-Dumont T, Robinot N, Hammet F, Odefrey F, Tsimiklis H, Teo ZL, Thingholm LB, Young EL, Voegele C, Lonie A, Pope BJ, Roane TC, Bell R, Hu H, Shankaracharya, HuffCD, Ellis J, Li J, Makunin IV, John EM, Andrulis IL, Terry MB, Daly M, Buys SS, Snyder C, Lynch HT, Devilee P, Giles GG, Hopper JL, Feng BJ, Lesueur F, Tavtigian SV, Southey MC, Goldgar DE. Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers. Cancer Discov 2014;4:804-15
27. Damiola F, Pertesi M, Oliver J, Le Calvez-Kelm F, Voegele C, Young EL, Robinot N, Forey N, Durand G, Vallee MP, Tao K, Roane TC, Williams GJ, Hopper JL, Southey MC, Andrulis IL, John EM, Goldgar DE, Lesueur F, Tavtigian SV. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res 2014;16:R58
28. Garritano S, Gemignani F, Voegele C, Nguyen-Dumont T, Le Calvez-Kelm F, De Silva D, Lesueur F, Landi S, Tavtigian SV. Determining the effectiveness of High Resolution Melting analysis for SNP genotyping and mutation scanning at the TP53 locus. BMC Genet 2009;10:5
29. Sawyer S, Mitchell G, McKinley J, Chenevix-Trench G, Beesley J, Chen XQ, Bowtell D, Trainer AH, Harris M, Lindeman GJ, James PA. A role for common genomic variants in the assessment of familial breast cancer. J Clin Oncol 2012;30: 4330-6
30. Thompson ER, Gorringe KL, Rowley SM, Wong-Brown MW, McInerny S, Li N, Trainer AH, Devereux L, Doyle MA, Li J, Lupat R, Delatycki MB, LifePool I, Mitchell G, James PA, Scott RJ, Campbell IG. Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls. Breast Cancer Res 2015;17:111
31. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60
32. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods 2012;9:179-81
33. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97:813-22
34. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Breast Cancer Susceptibility C, Easton DF, Stratton MR, Rahman N. ATM mutations that cause ataxiatelangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-5
35. Consortium CBCC-C. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10. studies. Am J Hum Genet 2004;74:1175-82
36. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR, Consortium CH-BC. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9
37. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittomaki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014;371:497-506
38. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, Besenbacher S, Lundin P, Stacey SN, Gudmundsson J, Magnusson OT, le Roux L, Orlygsdottir G, Helgadottir HT, Johannsdottir H, Gylfason A, Tryggvadottir L, Jonasson JG, de Juan A, Ortega E, Ramon-Cajal JM, Garcia-Prats MD, Mayordomo C, Panadero A, Rivera F, Aben KK, van Altena AM, Massuger LF, Aavikko M, Kujala PM, StaffS, Aaltonen LA, Olafsdottir K, Bjornsson J, Kong A, Salvarsdottir A, Saemundsson H, Olafsson K, Benediktsdottir KR, Gulcher J, Masson G, Kiemeney LA, Mayordomo JI, Thorsteinsdottir U, Stefansson K. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011;43:1104-7
39. Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, Fraser L, Gentry-Maharaj A, Hayward J, Philpott S, Anderson C, Edlund CK, Conti D, Harrington P, Barrowdale D, Bowtell DD, Alsop K, Mitchell G, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Bogdanova N, Durst M, Hillemanns P, Ovarian Cancer Association C, Odunsi K, Whittemore AS, Karlan BY, Dork T, Goode EL, Menon U, Jacobs IJ, Antoniou AC, Pharoah PD, Gayther SA. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN genes in Women with Ovarian Cancer. J Natl Cancer Inst 2015;107:djv214
40. Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-11
41. Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P, Bedenham T, Bradwell AR, Easton DF, Lennox GG, Haites N, Byrd PJ, Taylor AM. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998;62:334-45
42. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat 2006;27:1122-8
43. Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly MJ, Buys SM, Southey MC, Andrulis I, John EM, Bcfr, kConFab, Khanna KK, Hopper JL, Oefner PJ, Lakhani S, Chenevix-Trench G. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res 2011;13:R73